Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Keratosis, Actinic 3Carcinoma, Basal Cell 3Urinary Bladder Neoplasms 2Skin Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Squamous Cell 2Stomatitis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Head and Neck Neoplasms 1Glioblastoma 1Depression 1Deglutition Disorders 1Carcinoma, Non-Small-Cell Lung 1Anxiety Disorders 1

Interventions

Therapeutics 29Psychiatric Rehabilitation 20Cognitive Behavioral Therapy 12Early Intervention, Educational 10Psilocybin 9Ketamine 9Methods 8Saline Solution 7Yoga 6Surveys and Questionnaires 6Mindfulness-Based Cognitive Therapy 6Esketamine 6Counseling 6Psychosocial Intervention 5Mindfulness 5Methylphenidate 5Educational Status 5Behavior Therapy 5Acupuncture Therapy 5Interviews as Topic 4Exercise Therapy 4Exercise 4Escitalopram 4Control Groups 4Caregivers 4Psychotherapy 3Palliative Care 3Niacin 3Mindfulness-Based Stress Reduction 3Melatonin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Depression × Niacinamide × Clear all
NCT00302744 2025-03-13

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase 1/2 Completed
12 enrolled

Anxiety Disorders, Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡